Bottom Line: With Linton’s track record of overpaying for assets that support the promotional story he wanted to tell, we expect the new management team will be quick to write off legacy assets to make sure they have a low bar to jump over to please investors going forward.
Bottom Line: We expect other producers with outdoor licenses will also fail to grow the amount of cannabis they originally planned for. Next year capacity from outdoor grows should be substantial and will likely hurt the profitability and demand for large scale, but low-quality, greenhouse-grown cannabis.
Bottom Line: One year into medical legalization, Oklahoma already has more medical patients as a percentage of the population than Canada has today. The lack of a medical condition qualifier to gain access to the market is driving extremely fast growth. Oklahoma is looking like one of the most attractive medical cannabis states in America.
Bottom Line: If this lawsuit leads to faster cultivation approvals for cannabis research it will definitely speed up the pace of research. More research to support the medical use of cannabis could speed up national legalization and the pace of patent approvals for cannabis-based medicine.
Bottom Line: This level of support for legalization is in line with where the U.S. was in 2009. 66% of Americans in contrast now support nationwide legalization showing us the UK still has a ways to go before we see rapid change in cannabis laws. In the past year, UK support for cannabis increased from 43% to 47% while those against decreased from 41% to 30%, showing progress.
Global pot stocks broke a two-week streak of positive performance this week, falling 2%. The departure of Canopy Growth CEO Bruce Linton had a negative effect on sentiment in the space.
From the peak in March, cannabis stocks are down 22%, but still 25% above the lows in December 2018. U.S. stocks fell in line with Canadian peers, falling 2%. We expect U.S. stocks to outperform Canadian names the rest of the year with better regulatory catalysts and growth prospects. MSOs are up 11% year to date while Canadian growers are up 25%, but this trend should reverse as we move through the year.
The overall marijuana index underperformed the S&P and TSX by 3.7% and 3.0% respectively.
Stocks will remain seasonally weak as we go into the fall, but U.S. stocks have the benefit of some big regulatory catalysts potentially on the horizon this year.
Longer-term, with the Canadian market legalized, we expect retail and wholesale price compression from a legal oversupply by the end of 2019. Falling cannabis prices will pressure producer stocks later in 2019 or early 2020. After a shakeout, the remaining stocks will be better positioned as long-term buying opportunities.
- Massachusetts Releases New Draft Rules for Marijuana Industry
- MedMen Announces Partnership with Non-profit Epilepsy Florida
- South Carolina Hemp Production Industry Soars
- New Jersey Governor to Sign Medical Marijuana Expansion Bill
- Cresco Labs Taps Former Sears Exec for CIO Post
- Idaho Medicinal Cannabis Legalization Campaign Gets Underway
- Tilray Recruits Five Senior Managers for European Expansion
- 1 In 4 Canadian Medical Cannabis Users Struggle to Access Marijuana
- CannTrust Lowers Production Estimates for First Outdoor Grow Season
- Ontario to Issue 50 New Cannabis Retail Licenses Next Month
- Aptly Named “Ombudsman” Dealing with Consumer Cannabis Complaints in Ontario
- Britain Should Legalize Recreational Cannabis Within Five Years, Claims Conservative MP
- UK Government Implored to Relax Cannabis Prescription Rules
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.